Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

Cancer Letters

Volumn 136, Issue 2, 1999, Pages 129-136

  Halmos, Gabor ^a,b   Nagy, Attila ^a,b   Lamharzi, Najib ^a,b   Schally, Andrew V ^a,b  

^a Endocrine   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; LH RH receptors; Targeted chemotherapeutic agents

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN DERIVATIVE; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; HORMONE RECEPTOR; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL MEMBRANE; DOXORUBICIN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; RADIOLIGAND ASSAY; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0032935902     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00316-4     Document Type: Article

References (31)

1. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocrinol. Rev. 11:1990;221-265.
2. Schally A.V., Comaru-Schally A.M. Hypothalamic and Other Peptide Hormones. Chapter 71 Holland J.F., Frei E. III, Bast R.C. Jr, Kufe D.E., Morton D.L., Weichselbaum R.R. Cancer Medicine. 4th edn. 1997;1067 Williams and Wilkins, Baltimore, MD.
3. Schally A.V. The use of LH-RH analogs in Gynecology and Tumor Therapy. Belfort P., Pinotti J.A., Eskes T.K.A.B. Advances in Gynecology and Obstetrics, General Gynecology. 6:1989;3 Parthenon Publishing, Carnforth, UK.
4. Mathé G., Keiling R., Provot G., Vo Van M.L., Gastiaburu J., Vannetzel J.M., Despax R., Jasmin C., Levi F., Musset M., Machover D., Ribaud R., Misset J.L. LH-RH agonist: Breast and prostate cancer. Klijn J.G.M., Paridaens R., Foekens J.A., et al. Hormonal manipulation of cancer: Peptides, growth factors, and new (anti) steroidal agents. 1987;315 Raven Press, New York.
5. Szende B., Srkalovic G., Groot K., Lapis K., Schally A.V. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J. Natl. Cancer Inst. 82:1990;513-517.
6. Yano T., Pinski J., Szepeshazi K., Halmos G., Radulovic S., Groot K., Schally A.V. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 73:1994;1229-1238.
7. Miller W.R., Scott W.N., Morris R., Fraser H.M., Sharpe R.M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 313:1985;231-233.
8. Eidne A., Flanagan C.A., Harris N.S., Millar R.P. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J. Clin. Endocrinol. Metab. 64:1987;425-432.
9. Segal-Abramson T., Kitroser H., Levy H., Schally A.V., Sharoni Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc. Natl. Acad. Sci. USA. 89:1992;2336-2339.
10. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3:1989;137-147.
11. Baumann H.H., Kiesel I., Kaufman M., Bastert G., Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res. Treat. 25:1993;37-46.
12. Janáky T., Juhász A., Bajusz S., Csernus V., Srkalovic G., Bokser L., Milovanovic S., Redding T.W., Rékasi Z, Nagy A., Schally A.V. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc. Natl. Acad. Sci. USA. 89:1992;972-976.
13. Milovanovic S.R., Radulovic S., Schally A.V. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor. Breast Cancer Res. Treat. 24:1992;147-158.
14. Schally A.V., Nagy A., Szepeshazi K., Pinski J., Halmos G., Armatis P., Miyazaki M., Comaru-Schally A.M., Yano T., Emons G. LHRH analogs with cytotoxic radicals. Filicori M., Flamigni C. Treatment with Gn-RH analogs: Controversies and perspectives. 1996;33 Parthenon Publishing, Carnforth, UK.
15. Szepeshazi K., Schally A.V., Halmos G., Szoke B., Groot K., Nagy A. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res. Treat. 40:1996;129-139.
16. Nagy A., Schally A.V., Armatis P., Szepeshazi K., Halmos G., Kovacs M., Zarandi M., Groot K., Miyazaki M., Jungwirth A., Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. USA. 93:1996;7269-7273.
17. Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 55:1995;280-287.
18. Halmos G., Schally A.V., Pinski J., Vadillo-Buenfil M., Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA. 93:1996;2398-2402.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann. Biochem. 72:1976;248-254.
20. Lamharzi N., Halmos G., Armatis P., Schally A.V. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int. J. Oncol. 12:1998;671-675.
21. Kakar S.S., Musgrove L.C., Devor C.D., Sellers J.C., Neill J.D. Cloning, sequencing and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem. Biophys. Res. Commun. 189:1992;289-295.
22. Munson P.J., Rodbard D.A. A versatile computerized approach for characterization of ligand binding systems. Ann. Biochem. 107:1980;220-239.
23. McPherson G.A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J. Pharmacol. Methods. 14:1985;213-228.
24. Scatchard B. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51:1949;660-672.
25. Emons G., Schally A.V. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancer. Hum. Reprod. 9:1994;1364-1379.
26. 6] luteinizinghormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int. J. Oncol. 12:1998;489-498.
27. Qayum A., Gullick W., Clayton R.C., Sikora K., Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br. J. Cancer. 62:1990;96-99.
28. Miyazaki M., Nagy A., Schally A.V., Lamharzi N., Halmos G., Szepeshazi K., Groot K., Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J. Natl. Cancer Inst. 89:1997;1803-1809.
29. Szepeshazi K., Schally A.V., Nagy A., Halmos G., Groot K. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs. 8:1997;974-987.
30. Jungwirth A., Schally A.V., Nagy A., Pinski J., Groot K., Galvan G., Szepeshazi K., Halmos G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int. J. Oncol. 10:1997;877-884.
31. Mullen P., Bramley T., Menzies G., Miller B. Failure to detect gonadotrophin-releasing hormone receptors in human benign and malignant breast tissue and in MCF-7 and MDA-MB-231 cancer cells. Eur. J. Cancer. 29A:1993;248-252.